UY31376A1 - Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapéuticas - Google Patents

Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapéuticas

Info

Publication number
UY31376A1
UY31376A1 UY31376A UY31376A UY31376A1 UY 31376 A1 UY31376 A1 UY 31376A1 UY 31376 A UY31376 A UY 31376A UY 31376 A UY31376 A UY 31376A UY 31376 A1 UY31376 A1 UY 31376A1
Authority
UY
Uruguay
Prior art keywords
quinazolinadiona
preparation
derivatives
therapeutic applications
compounds
Prior art date
Application number
UY31376A
Other languages
English (en)
Inventor
Vivet Bertrand
Seyer Andre
Nave Jean-Francois
Muzet Nicolas
Marciniak Gilbert
Glaess Christophe
Clauss Annie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31376A1 publication Critical patent/UY31376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion tiene por objeto los compuestos de formula (I) en el estado de base, de hidrato, de solvato, o de sus mezclas. La invencion se refiere igualmente al procedimiento de preparacion así como a las utilizaciones en terapéutica de los compuestos de formula (I).
UY31376A 2007-10-03 2008-10-03 Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapéuticas UY31376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706931A FR2921926B1 (fr) 2007-10-03 2007-10-03 Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.

Publications (1)

Publication Number Publication Date
UY31376A1 true UY31376A1 (es) 2009-05-29

Family

ID=39470387

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31376A UY31376A1 (es) 2007-10-03 2008-10-03 Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapéuticas

Country Status (40)

Country Link
US (1) US8242126B2 (es)
EP (1) EP2205593B1 (es)
JP (1) JP5411143B2 (es)
KR (1) KR20100082345A (es)
CN (1) CN101842368B (es)
AR (1) AR070655A1 (es)
AU (1) AU2008337382B2 (es)
BR (1) BRPI0818690A2 (es)
CA (1) CA2701150C (es)
CL (1) CL2008002946A1 (es)
CO (1) CO6270227A2 (es)
CR (1) CR11327A (es)
CY (1) CY1117461T1 (es)
DK (1) DK2205593T3 (es)
DO (1) DOP2010000089A (es)
EA (1) EA018766B1 (es)
EC (1) ECSP10010058A (es)
ES (1) ES2567567T3 (es)
FR (1) FR2921926B1 (es)
GT (1) GT201000069A (es)
HN (1) HN2010000572A (es)
HR (1) HRP20160359T1 (es)
HU (1) HUE028770T2 (es)
IL (1) IL204814A0 (es)
MA (1) MA31832B1 (es)
MX (1) MX2010003495A (es)
MY (1) MY153763A (es)
NI (1) NI201000039A (es)
NZ (1) NZ584430A (es)
PA (1) PA8797701A1 (es)
PE (1) PE20090960A1 (es)
PL (1) PL2205593T3 (es)
SI (1) SI2205593T1 (es)
SV (1) SV2010003514A (es)
TN (1) TN2010000130A1 (es)
TW (1) TWI421076B (es)
UA (1) UA99485C2 (es)
UY (1) UY31376A1 (es)
WO (1) WO2009077680A1 (es)
ZA (1) ZA201002307B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8107260B2 (en) * 2007-11-15 2012-01-31 Illinois Tool Works Inc. EMI shielding and environmental seal device
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
KR101116234B1 (ko) * 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
AU2011261164A1 (en) 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
AR090836A1 (es) 2012-04-24 2014-12-10 Chugai Pharmaceutical Co Ltd Derivados de benzamida
CN104379568A (zh) * 2012-04-24 2015-02-25 中外制药株式会社 喹唑啉二酮衍生物
EP2854780B1 (en) 2012-06-05 2017-08-30 University Of Kansas Inhibitors of respiratory syncytial virus
WO2015003879A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
AU2014338070A1 (en) 2013-10-23 2016-05-05 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CZ2015601A3 (cs) * 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CN107267455A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种嵌合抗原受体nk细胞的制备方法
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
WO1996036638A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
JP2002308774A (ja) * 2001-04-12 2002-10-23 Nippon Zoki Pharmaceut Co Ltd Ｉｖ型ホスホジエステラーゼ選択的阻害剤
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
WO2007067946A2 (en) 2005-12-07 2007-06-14 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (cll)

Also Published As

Publication number Publication date
EP2205593A1 (fr) 2010-07-14
JP2010540602A (ja) 2010-12-24
PL2205593T3 (pl) 2016-09-30
CL2008002946A1 (es) 2010-02-12
MA31832B1 (fr) 2010-11-01
ECSP10010058A (es) 2010-04-30
KR20100082345A (ko) 2010-07-16
CR11327A (es) 2010-09-13
HRP20160359T1 (hr) 2016-05-06
CN101842368B (zh) 2014-03-12
AU2008337382A1 (en) 2009-06-25
MX2010003495A (es) 2010-04-21
PA8797701A1 (es) 2009-05-15
CO6270227A2 (es) 2011-04-20
JP5411143B2 (ja) 2014-02-12
WO2009077680A1 (fr) 2009-06-25
EA201070424A1 (ru) 2011-04-29
GT201000069A (es) 2012-03-26
DOP2010000089A (es) 2010-05-15
PE20090960A1 (es) 2009-08-10
AU2008337382B2 (en) 2013-11-21
EA018766B1 (ru) 2013-10-30
CY1117461T1 (el) 2017-04-26
UA99485C2 (ru) 2012-08-27
CN101842368A (zh) 2010-09-22
HN2010000572A (es) 2013-03-11
IL204814A0 (en) 2010-11-30
TN2010000130A1 (fr) 2011-09-26
FR2921926B1 (fr) 2009-12-04
NI201000039A (es) 2010-08-13
HUE028770T2 (en) 2016-12-28
DK2205593T3 (en) 2016-04-18
FR2921926A1 (fr) 2009-04-10
US20100298298A1 (en) 2010-11-25
NZ584430A (en) 2011-11-25
EP2205593B1 (fr) 2016-01-13
ES2567567T3 (es) 2016-04-25
BRPI0818690A2 (pt) 2015-04-14
SV2010003514A (es) 2011-01-31
AR070655A1 (es) 2010-04-28
SI2205593T1 (sl) 2016-05-31
MY153763A (en) 2015-03-13
TW200922591A (en) 2009-06-01
TWI421076B (zh) 2014-01-01
CA2701150C (fr) 2016-08-16
CA2701150A1 (fr) 2009-06-25
US8242126B2 (en) 2012-08-14
ZA201002307B (en) 2011-06-29

Similar Documents

Publication Publication Date Title
UY31376A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapéuticas
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
UY30804A1 (es) Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones
DOP2010000153A (es) Derivados de pirimidina para el tratamiento de asma, epoc, rinitis alergica, conjuntivis alergica, dermatitis atopica, cancer,hepatitis b, hepatitis c, vih, vph, infecciones bacterianas y dermatosis
CR11491A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR10662A (es) Compuestos de metilpiridopirimidinona
CU20110212A7 (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
UY30863A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
UY30938A1 (es) Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones.
CR11452A (es) 5-((3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino)-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiflamatorios
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
UY29631A1 (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
DK1819704T3 (da) Pyrrolopyridin-2-carboxylsyre-amid-derivat anvendelig som inhibitor af glycogenphosphorylase
UY29684A1 (es) Derivados de piperidina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
CR20110527A (es) Derivados de 1-alquil-cinolin-4(1h)-ona, su preparación y su aplicación en terapéutica
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
UY32575A (es) Derivados de 1h-pirazolo[4,3-c]isoquinoleínas, su preparación y su aplicación en terapéutica
CU20100100A7 (es) Derivados de pirimidina para el tratamiento de asma, epoc, rinitis alérgica, conjuntivitis alérgica, dermatitis atópica, cáncer, hepatitis b, hepatitis c, vih, infecciones bacterianas y dermatosis
DOP2009000032A (es) Derivados de feniloxianilina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171019